2 February 2012 - Germany-based biopharmaceutical company Agennix AG (ETR:AGX) said on Thursday that it decided to follow the recommendation of the study Data Safety Monitoring Board (DSMB) and halt patient enrolment and treatment in its Phase II/III OASIS trial with talactoferrin in severe sepsis.<...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up